Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

A Phase 2 Randomized, Double-Blind, Placebo-controlled Trial of Oral Camostat Mesylate for Early Treatment of COVID-19 Outpatients Showed Shorter Illness Course and Attenuation of Loss of Smell and Taste

Geoffrey Chupp, Anne Spichler-Moffarah, Ole S. Søgaard, Denise Esserman, James Dziura, Lisa Danzig, Reetika Chaurasia, Kailash P. Patra, Aryeh Salovey, Angela Nunez, Jeanine May, Lauren Astorino, Amisha Patel, Stephanie Halene, Jianhui Wang, Pei Hui, Prashant Patel., Jing Lu, Fangyong Li, Geliang Gan, Stephen Parziale, Lily Katsovich, Gary V. Desir, Joseph M. Vinetz
doi: https://doi.org/10.1101/2022.01.28.22270035
Geoffrey Chupp
aSection of Pulmonary, Critical Care, and Sleep Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA
M.D
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anne Spichler-Moffarah
bSection of Infectious Diseases, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA
M.D, Ph.D.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ole S. Søgaard
cDepartment of Clinical Medicine and Department of Infectious Diseases, Aarhus University, Aarhus, Denmark
M.D, Ph.D.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Denise Esserman
dYale Center for Analytical Sciences, Yale School of Public Health, New Haven, CT, USA
Ph.D.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
James Dziura
dYale Center for Analytical Sciences, Yale School of Public Health, New Haven, CT, USA
Ph.D.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lisa Danzig
eAmicitiam Partners, San Francisco, CA
M.D., M.P.H.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Reetika Chaurasia
bSection of Infectious Diseases, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA
Ph.D.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kailash P. Patra
bSection of Infectious Diseases, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA
Ph.D.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Aryeh Salovey
bSection of Infectious Diseases, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA
B.S.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Angela Nunez
fYale Center for Clinical Investigation, Yale School of Medicine, New Haven, CT, USA
MPH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jeanine May
fYale Center for Clinical Investigation, Yale School of Medicine, New Haven, CT, USA
APRN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lauren Astorino
fYale Center for Clinical Investigation, Yale School of Medicine, New Haven, CT, USA
APRN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Amisha Patel
gSection of Hematology, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA
B.S.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stephanie Halene
gSection of Hematology, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA
M.D., Ph.D.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jianhui Wang
hDepartment of Pathology, Yale School of Medicine New Haven, CT, USA
Ph.D.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pei Hui
hDepartment of Pathology, Yale School of Medicine New Haven, CT, USA
Ph.D., M.D.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Prashant Patel.
iInvestigation Drug Service, Yale New Haven Hospital, New Haven, CT, USA
Pharm.D
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jing Lu
iInvestigation Drug Service, Yale New Haven Hospital, New Haven, CT, USA
Ph.D., R.Ph.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Fangyong Li
dYale Center for Analytical Sciences, Yale School of Public Health, New Haven, CT, USA
M.P.H., M.S.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Geliang Gan
dYale Center for Analytical Sciences, Yale School of Public Health, New Haven, CT, USA
M.S.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stephen Parziale
dYale Center for Analytical Sciences, Yale School of Public Health, New Haven, CT, USA
M.Sc.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lily Katsovich
dYale Center for Analytical Sciences, Yale School of Public Health, New Haven, CT, USA
M.S., M.B.A.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gary V. Desir
iInvestigation Drug Service, Yale New Haven Hospital, New Haven, CT, USA
M.D.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joseph M. Vinetz
bSection of Infectious Diseases, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA
M.D.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: joseph.vinetz{at}yale.edu
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Importance Early treatment of mild SARS-CoV-2 infection might lower the risk of clinical deterioration in COVID-19.

Objective To determine whether oral camostat mesylate would reduce upper respiratory SARS-CoV-2 viral load in newly diagnosed outpatients with mild COVID-19, and would lead to improvement in COVID-19 symptoms.

Design From June, 2020 to April, 2021, we conducted a randomized, double-blind, placebo-controlled phase 2 trial.

Setting Single site, academic medical center, outpatient setting in Connecticut, USA.

Participants Of 568 COVID-19 positive potential adult participants diagnosed within 3 days of study entry and assessed for eligibility, 70 were randomized and 498 were excluded (198 did not meet eligibility criteria, 37 were not interested, 265 were excluded for unknown or other reasons). The primary inclusion criteria were a positive SARS-CoV-2 nucleic acid amplification result in adults within 3 days of screening regardless of COVID-19 symptoms.

Intervention Treatment was 7 days of oral camostat mesylate, 200 mg po four times a day, or placebo.

Main Outcomes and Measures The primary outcome was reduction of 4-day log10 nasopharyngeal swab viral load by 0.5 log10 compared to placebo. The main prespecified secondary outcome was reduction in symptom scores as measured by a quantitative Likert scale instrument, Flu-PRO-Plus modified to measure changes in smell/taste measured using FLU-PRO-Plus.

Results Participants receiving camostat had statistically significant lower quantitative symptom scores (FLU-Pro-Plus) at day 6, accelerated overall symptom resolution and notably improved taste/smell, and fatigue beginning at onset of intervention in the camostat mesylate group compared to placebo. Intention-to-treat analysis demonstrated that camostat mesylate was not associated with a reduction in 4-day log10 NP viral load compared to placebo.

Conclusions and relevance The camostat group had more rapid resolution of COVID-19 symptoms and amelioration of the loss of taste and smell. Camostat compared to placebo was not associated with reduction in nasopharyngeal SARS-COV-2 viral load. Additional clinical trials are warranted to validate the role of camostat mesylate on SARS-CoV-2 infection in the treatment of mild COVID-19.

Trial registration: Clinicaltrials.gov, NCT04353284 (04/20/20) (https://clinicaltrials.gov/ct2/show/NCT04353284?term=camostat+%2C+yale&draw=2&rank=1)

Question Will early treatment of COVID-19 with a repurposed medication, camostat mesylate, improve clinical outcomes?

Findings In this phase 2 randomized, double-blind placebo-controlled clinical trial that included 70 adults with early COVID-19, the oral administration of camostat mesylate treatment within 3 days of diagnosis prevented the loss of smell/taste and reduced the duration of illness.

Meaning In the current COVID-19 pandemic, phase III testing of an inexpensive, repurposed drug for early COVID-19 is warranted.

Competing Interest Statement

The authors have declared no competing interest.

Clinical Trial

NCT04353284

Funding Statement

This investigator-initiated study was supported by Kenneth C. Griffin, the Prostate Cancer Foundation, the COVID-19 Early Treatment Fund, and the Harrington Discovery Institute, institutional funds from the Department of Internal Medicine at the Yale School of Medicine, and the Yale Center for Clinical Investigation. This study was partially supported by the United State Public Health Service grant, 5UL1RR024139. Ono Pharmaceuticals provided the study drug, FOIPAN, at no cost to the study but had no input into study design or the writing or content of the manuscript.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The Yale University Human Subjects Protection Program/IRB approved this study.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

All data produced in the present study are available upon reasonable request to the authors

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted January 31, 2022.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
A Phase 2 Randomized, Double-Blind, Placebo-controlled Trial of Oral Camostat Mesylate for Early Treatment of COVID-19 Outpatients Showed Shorter Illness Course and Attenuation of Loss of Smell and Taste
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
A Phase 2 Randomized, Double-Blind, Placebo-controlled Trial of Oral Camostat Mesylate for Early Treatment of COVID-19 Outpatients Showed Shorter Illness Course and Attenuation of Loss of Smell and Taste
Geoffrey Chupp, Anne Spichler-Moffarah, Ole S. Søgaard, Denise Esserman, James Dziura, Lisa Danzig, Reetika Chaurasia, Kailash P. Patra, Aryeh Salovey, Angela Nunez, Jeanine May, Lauren Astorino, Amisha Patel, Stephanie Halene, Jianhui Wang, Pei Hui, Prashant Patel., Jing Lu, Fangyong Li, Geliang Gan, Stephen Parziale, Lily Katsovich, Gary V. Desir, Joseph M. Vinetz
medRxiv 2022.01.28.22270035; doi: https://doi.org/10.1101/2022.01.28.22270035
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
A Phase 2 Randomized, Double-Blind, Placebo-controlled Trial of Oral Camostat Mesylate for Early Treatment of COVID-19 Outpatients Showed Shorter Illness Course and Attenuation of Loss of Smell and Taste
Geoffrey Chupp, Anne Spichler-Moffarah, Ole S. Søgaard, Denise Esserman, James Dziura, Lisa Danzig, Reetika Chaurasia, Kailash P. Patra, Aryeh Salovey, Angela Nunez, Jeanine May, Lauren Astorino, Amisha Patel, Stephanie Halene, Jianhui Wang, Pei Hui, Prashant Patel., Jing Lu, Fangyong Li, Geliang Gan, Stephen Parziale, Lily Katsovich, Gary V. Desir, Joseph M. Vinetz
medRxiv 2022.01.28.22270035; doi: https://doi.org/10.1101/2022.01.28.22270035

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (431)
  • Allergy and Immunology (757)
  • Anesthesia (221)
  • Cardiovascular Medicine (3298)
  • Dentistry and Oral Medicine (365)
  • Dermatology (280)
  • Emergency Medicine (479)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1173)
  • Epidemiology (13385)
  • Forensic Medicine (19)
  • Gastroenterology (899)
  • Genetic and Genomic Medicine (5158)
  • Geriatric Medicine (482)
  • Health Economics (783)
  • Health Informatics (3276)
  • Health Policy (1143)
  • Health Systems and Quality Improvement (1193)
  • Hematology (432)
  • HIV/AIDS (1019)
  • Infectious Diseases (except HIV/AIDS) (14637)
  • Intensive Care and Critical Care Medicine (913)
  • Medical Education (478)
  • Medical Ethics (127)
  • Nephrology (525)
  • Neurology (4930)
  • Nursing (262)
  • Nutrition (730)
  • Obstetrics and Gynecology (886)
  • Occupational and Environmental Health (795)
  • Oncology (2524)
  • Ophthalmology (728)
  • Orthopedics (282)
  • Otolaryngology (347)
  • Pain Medicine (323)
  • Palliative Medicine (90)
  • Pathology (544)
  • Pediatrics (1302)
  • Pharmacology and Therapeutics (551)
  • Primary Care Research (557)
  • Psychiatry and Clinical Psychology (4218)
  • Public and Global Health (7512)
  • Radiology and Imaging (1708)
  • Rehabilitation Medicine and Physical Therapy (1016)
  • Respiratory Medicine (980)
  • Rheumatology (480)
  • Sexual and Reproductive Health (498)
  • Sports Medicine (424)
  • Surgery (549)
  • Toxicology (72)
  • Transplantation (236)
  • Urology (205)